###### Strengths and limitations of this study

-   We analysed the risk of different cancer types in patients with chronic obstructive pulmonary disease (COPD) and stratified them by disease severity according to the number of prescription drugs.

-   The patients with COPD in our study were treated with COPD medications and were over 40 years old. Our study groups were matched by age and gender, and the data were analysed using the Cox model, including patient comorbidities. Our method differed from the standardised incidence ratio, which cannot adjust for comorbidities or medications.

-   This study was a nationwide cohort study with a large number of participants, comprehensive enrolment of patients with COPD, and long-term follow-up.

-   The limitations included lack of COPD severity information and cancer staging from the claims database.

-   The data lacked consideration of other factors associated with COPD and cancer, such as lifestyle choices, physical activity and socioeconomic status.

Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is not fully reversible, and the disease is usually progressive and associated with lung inflammatory responses to noxious particles or gases.[@R1] COPD was the sixth most common cause of death worldwide in 1990, and it was predicted to become the third most common cause by 2020.[@R2] Cigarette smoking is the most common cause of COPD, and smoking is a risk factor for lung cancer. Lung cancer risk increases with decreasing lung function in patients with COPD.[@R3] The systemic effects of smoking and chronic systemic inflammation responses in patients with COPD contribute to the development of respiratory symptoms, functional impairment, and chronic comorbidities and include extrapulmonary cancers.[@R4] A previous study demonstrated that COPD was associated with an increased risk of lung cancer mortality and extrapulmonary cancer mortality.[@R5] In other cohort studies,[@R4] patients with COPD had increased mortality and risk of extrapulmonary cancers. However, previous studies have been limited by few participants or studying only populations at local hospitals and none of the other studies mention specific types of extrapulmonary cancers. The aim of this study was to use a nationwide cohort database to examine the incidence of malignant diseases, including specific cancer types, in Taiwanese patients after being diagnosed with COPD compared with Taiwanese patients without COPD.

Materials and methods {#s2}
=====================

Ethics statement {#s2a}
----------------

This study was conducted using an unidentifiable claims database provided by the National Health Insurance (NHI), and the principal investigator was requested to sign an agreement regarding compliance with the Computer-Processed Personal Data Protection Act during the proposal application. In addition, the policy of our Institutional Review Board (IRB) is consistent with the principles of the Declaration of Helsinki.

Source of data {#s2b}
--------------

Taiwan launched a single-payer NHI programme in 1995. The National Health Insurance Research Database (NHIRD), a medical claims database, was established and released for research purposes. The NHIRD contains all inpatient and outpatient claims data in Taiwan, including patients\' demographic characteristics, dates of clinical visits, disease diagnoses, prescription medications and expenditure amounts. More than 99% of the total population of Taiwan was enrolled in the NHI programme. In this study, we analysed the claim data of one million beneficiaries (from 1 January 2000 to 31 December 2011) randomly sampled from all of the beneficiaries registered in 2000.

Study groups {#s2c}
------------

In the present study, the definition of a patient with COPD was a patient with a discharge diagnosis of COPD (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes: 490--492, 496) or at least three ambulatory visits for COPD who was also prescribed COPD medications, including short-acting β2 agonists (SABA), long-acting β2 agonists (LABA), theophylline, inhaled short-acting muscarinic antagonists (SAMA), long-acting muscarinic antagonists (LAMA), combination inhaled corticosteroid (ICS)/LABA, methylxanthines (MTX) and anticholinergics (AC). Included patients were those over 40 years of age who received a diagnosis of COPD between 1 January 2000 and 31 December 2010. The index date was the date of the first COPD diagnosis. Patients with a history of malignancy disorders (ICD-9-CM codes 140 to 208) before the index date were excluded. During the study period, more than one readmission event may have occurred for the same patient; only the data from the first-time hospitalisation record for COPD were analysed to ensure the independence of observations. In total, 13 289 patients with COPD were retrieved and analysed.

The control participants were selected from the remaining patients without COPD and with no history of malignancy before the index date. Patients who were treated with any of the above COPD medications were also excluded. Considering that cancer was a rare event and a stratified analysis for seven cancer types was used in our study, patients with COPD were matched 1:2 for age and gender to the control participants without COPD. In total, 26 578 patients without COPD or malignancy were selected as controls. Case and control participants were followed from the index date to malignancy diagnosis, death or the end of study follow-up (31 December 2011), whichever came first.

Definition of malignancy cases {#s2d}
------------------------------

The Registry of Catastrophic Illness Database was used in cancer diagnosis. When a patient is diagnosed by a physician as having a malignancy, under Ministry of Health and Welfare guidelines, the patient can submit related information and apply for a catastrophic illness certificate. The application is formally reviewed by more than two physicians. Patients with in situ malignancies were excluded from this study because patients with in situ malignancies do not qualify for a catastrophic illness certificate.

Comorbidities and medication measures {#s2e}
-------------------------------------

Baseline comorbidities were assessed for 1 year before the index date. They included chronic kidney disease, liver disease, diabetes and hyperlipidaemia, and were recognised by the ICD-9-CM codes used to define each condition. COPD medication use on the index date was recorded. We examined the use of oral steroids, SABA, LABA, theophylline, ICS, SAMA, LAMA, ICS/LABA, MTX and AC. For estimating the effect of the number of COPD medications, patients with COPD in our study were divided into three groups: only one type of COPD medication, two types of COPD medication and more than two types of COPD medication.

Statistical analysis {#s2f}
--------------------

We described the demographic characteristics of the patients, including age, gender, Charlson comorbidity index, comorbidities and COPD medications. Continuous variables are presented as the means with SDs, and discrete variables are presented as counts and percentages. The χ^2^ test was used for comparing categorical variables, and the differences among continuous variables were compared using Student\'s t-test. The proportion of patients with cancer was plotted by Kaplan-Meier curves with log-rank test for comparing the differences between patients with COPD and patients without COPD. The relative risk of cancer was estimated by Cox proportional regression analysis, which was adjusted for potential confounding variables, such as age, sex and comorbidities. The statistical significance was inferred at a two-sided p value of \<0.05. All of the statistical analyses were performed using the Statistical Analysis Software (SAS) System, V.9.4 (SAS Institute, Cary, North Carolina, USA). Kaplan-Meier curves were plotted using Stata V.12 (Stata Corp, College Station, Texas, USA).

Results {#s3}
=======

The characteristics and comorbidities of the study participants are shown in [table 1](#BMJOPEN2016013195TB1){ref-type="table"}. Overall, 13 289 patients with COPD enrolled in the study. The mean age±SD of the patients with COPD was 57.9±13.5 years. A 10-year age group distribution showed that 29.7% were 49 years of age or younger, 37.6% were 50--59 years, 14.9% were 60--69 years and 17.8% were 70 years of age or older. The average length of follow-up was 3.9 years from COPD diagnosis to patients being diagnosed with any type of cancers compared with 5.0 years in the control groups (p\<0.01). Patients with COPD were diagnosed with cancer (n=973, 73%) at significantly higher rates than patients without COPD (n=708, 2.7%; p\<0.01). The patients with COPD had a higher prevalence of comorbidities than the control group (p\<0.01), including cardiovascular disease, chronic kidney disease, liver disease, diabetes and dyslipidaemia.

###### 

Demographic characteristics and comorbidities of patients with/without COPD

  ---------------------------------------------------------------------
                            COPD, n (%)\   Non-COPD, n (%)\   p Value
                            (N=13 289)     (N=26 578)         
  ------------------------- -------------- ------------------ ---------
  Sex                                                         

   Male                     7148 (53.8)    14 296 (53.8)      1.00

   Female                   6141 (46.2)    12 282 (46.2)      

  Age (years)                                                 

   40--49                   3951 (29.7)    7906 (29.8)        1.00

   50--59                   4994 (37.6)    9983 (37.6)        

   60--69                   1980 (14.9)    3961 (14.9)        

   ≥70                      2364 (17.8)    4728 (17.8)        

   Mean±SD                  57.9±13.5      57.9±13.5          1.00

   Cancer                   973 (7.3)      708 (2.7)          \<0.01

  Time to cancer (years)                                      

   Mean±SD                  3.9±3.2        5.0±3.2            \<0.01

  Comorbidity                                                 

   Cardiovascular disease   473 (3.6)      36 (0.1)           \<0.01

   Chronic kidney disease   227 (1.7)      36 (0.1)           \<0.01

   Liver disease            309 (2.3)      70 (0.3)           \<0.01

   Diabetes                 797 (6.0)      155 (0.6)          \<0.01

   Hyperlipidaemia          191 (1.4)      38 (0.1)           \<0.01

  COPD medications                                            

   1                        7452 (56.1)                       --

   2                        3660 (27.5)                       

   ≥3                       2177 (16.4)                       
  ---------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease.

[Figure 1](#BMJOPEN2016013195F1){ref-type="fig"} shows the cumulative incidence rate of any type of cancer in patients with or without COPD from the index date until the first occurrence of the cancer using Kaplan-Meier methods. The patients with COPD had higher cancer incidence rates compared with patients without COPD (log-rank test: p\<0.01). [Table 2](#BMJOPEN2016013195TB2){ref-type="table"} shows that the adjusted HR (AHR) of developing cancer among patients with COPD was 2.8 (95% CI 2.6 to 3.1) compared with patients without COPD after adjusting for age, sex and comorbidities. For comparing the risk of cancer among each of the seven cancer types between patients with COPD and without COPD, the AHRs for each cancer type are reported in [figure 2](#BMJOPEN2016013195F2){ref-type="fig"}. Patients with COPD had significantly higher risks of lung (AHR 11.6; 95% CI 6.2 to 21.9), liver (AHR 5.0; 95% CI 2.4 to 10.4), colorectal (AHR 3.0; 95% CI 1.7 to 5.2), prostate (AHR 4.9; 95% CI 1.8 to 13.5) and oesophageal (AHR 6.0; 95% CI 1.1 to 32.7) cancer. Moreover, the stratified analysis of the cancer risk between patients with COPD and without COPD by age group and sex for any type of cancer and each of the seven cancer types is also presented ([figure 2](#BMJOPEN2016013195F2){ref-type="fig"}).

###### 

HR of developing cancer in relation to baseline characteristics of the study participants

  -----------------------------------------------------------------------------------
                            Crude HR\          p Value   AHR\*\             p Value
                            (95% CI)                     (95% CI)           
  ------------------------- ------------------ --------- ------------------ ---------
  Patients                                                                  

   COPD                     2.9 (2.7 to 3.2)   \<0.01    2.8 (2.6 to 3.1)   \<0.01

   Non-COPD                 1.0 (ref)                    1.0 (ref.)         

  Sex                                                                       

   Male                     1.3 (1.2 to 1.4)   \<0.01    1.3 (1.2 to 1.4)   \<0.01

   Female                   1.0 (ref)                    1.0 (ref)          

  Age (years)                                                               

   40--49                   1.0 (ref)                    1.0 (ref)          

   50--59                   1.7 (1.5 to 2.0)   \<0.01    1.7 (1.5 to 1.9)   \<0.01

   60--69                   2.4 (2.1 to 2.8)   \<0.01    2.4 (2.1 to 2.8)   \<0.01

   \>70                     1.5 (1.3 to 1.8)   \<0.01    1.6 (1.4 to 1.9)   \<0.01

  Comorbidity                                                               

   Cardiovascular disease   1.8 (1.2 to 2.5)   \<0.01    0.8 (0.6 to 1.2)   0.31

   Chronic kidney disease   2.2 (1.4 to 3.4)   \<0.01    1.0 (0.7 to 1.6)   0.84

   Liver disease            4.1 (3.1 to 5.3)   \<0.01    2.3 (1.8 to 3.1)   \<0.01

   Diabetes                 2.7 (2.2 to 3.4)   \<0.01    1.4 (1.1 to 1.8)   \<0.01

   Hyperlipidaemia          2.4 (1.6 to 3.9)   \<0.01    1.1 (0.7 to 1.8)   0.69
  -----------------------------------------------------------------------------------

\*AHR is based on Cox proportional hazard regression model with adjustment for age, sex and comorbidities.

AHR, adjusted HR; COPD, chronic obstructive pulmonary disease.

![Kaplan-Meier plot for cancer incidence between patients with COPD and patients without COPD. COPD, chronic obstructive pulmonary disease.](bmjopen2016013195f01){#BMJOPEN2016013195F1}

![The overall and stratified analyses for the incidence and HR of developing cancer between patients with COPD and patients without COPD among any type of cancer and the seven major cancer types. AHR, adjusted HR; COPD, chronic obstructive pulmonary disease.](bmjopen2016013195f02){#BMJOPEN2016013195F2}

Patients with COPD were divided into three groups according to the number of medications used to treat COPD, and [figure 3](#BMJOPEN2016013195F3){ref-type="fig"} shows the cumulative incidence rates of any type of cancer in patients with or without COPD. Patients had a higher risk of developing cancer when more bronchodilator medications were used.

![Kaplan-Meier plot of cumulative incidence rates of cancer among patients with COPD with different medications and patients without COPD. COPD, chronic obstructive pulmonary disease.](bmjopen2016013195f03){#BMJOPEN2016013195F3}

[Table 3](#BMJOPEN2016013195TB3){ref-type="table"} shows the AHR of developing cancer in patients with COPD who were taking multiple COPD medications compared with patients without COPD or patients with COPD who were treated with only one COPD medication after adjusting for age, sex and comorbidities. Patients with COPD who were treated with COPD medications had a 2.6-fold (95% CI 2.3 to 3.0), 3.0-fold (95% CI 2.6 to 3.4) and 3.3-fold (95% CI 2.8 to 3.9) risk of any type of cancer for one, two and more than two medication treatments, respectively, compared with patients without COPD. The AHR of developing cancer among patients with COPD who used more than two types of COPD medication was 1.2 (95% CI 1.0 to 1.5) compared with patients with COPD who only used one type of medication. In addition, the AHR of developing cancer was 1.6 (95% CI 1.4 to 1.8) in male patients with COPD compared with female patients with COPD after adjusting for age and comorbidities. Being elderly was associated with a higher risk of developing cancer (50--59, AHR 1.8 (95% CI 1.5 to 2.2); 60--69, AHR 2.5 (95% CI 2.1 to 3.1); \>70, AHR 2.2 (95% CI 1.8 to 2.7)). Liver disease and diabetes were associated with a higher risk of developing cancer after adjusting for age, sex and comorbidities (liver disease, AHR 2.3 (95% CI 1.7 to 3.1); diabetes, AHR 1.3 (95% CI 1.0 to 1.7)).

###### 

HR of developing cancer in relation to baseline characteristics and COPD medications of the study participants

                                 AHR of cancer among all study participants (95% CI)   p Value   AHR\* of cancer for patients with COPD alone (95% CI)   p Value
  ------------------------------ ----------------------------------------------------- --------- ------------------------------------------------------- ---------
  Patients                                                                                                                                               
   Non-COPD                      1.0 (ref)                                                       --                                                      
   COPD with only 1 medication   2.6 (2.3 to 3.0)                                      \<0.01    1.0 (ref)                                               
   COPD with 2 medication        3.0 (2.6 to 3.4)                                      \<0.01    1.1 (1.0 to 1.3)                                        0.16
   COPD with ≥3 medication       3.3 (2.8 to 3.9)                                      \<0.01    1.2 (1.0 to 1.5)                                        0.02
  Sex                                                                                                                                                    
   Male                          1.3 (1.2 to 1.4)                                      \<0.01    1.6 (1.4 to 1.8)                                        \<0.01
   Female                        1.0 (ref)                                                       1.0 (ref)                                               
  Age (years)                                                                                                                                            
   40--49                        1.0 (ref)                                                       1.0 (ref)                                               
   50--59                        1.7 (1.5 to 1.9)                                      \<0.01    1.8 (1.5 to 2.2)                                        \<0.01
   60--69                        2.4 (2.1 to 2.8)                                      \<0.01    2.5 (2.1 to 3.1)                                        \<0.01
   \>70                          1.6 (1.4 to 1.9)                                      \<0.01    2.2 (1.8 to 2.7)                                        \<0.01
  Comorbidity                                                                                                                                            
   Cardiovascular disease        0.8 (0.6 to 1.2)                                      0.27      0.8 (0.5 to 1.1)                                        0.15
   Chronic kidney disease        1.1 (0.7 to 1.7)                                      0.82      1.1 (0.7 to 1.7)                                        0.76
   Liver disease                 2.3 (1.8 to 3.1)                                      \<0.01    2.3 (1.7 to 3.1)                                        \<0.01
   Diabetes                      1.4 (1.1 to 1.8)                                      \<0.01    1.3 (1.0 to 1.7)                                        0.02
   Hyperlipidaemia               1.1 (0.7 to 1.8)                                      0.68      1.1 (0.7 to 1.8)                                        0.66

\*AHR is based on Cox proportional hazard regression model with adjustments for age, sex and comorbidities.

AHR, adjusted HR; COPD, chronic obstructive pulmonary disease.

Discussion {#s4}
==========

Cancer type in patients with COPD {#s4a}
---------------------------------

This is the first study to show the common types of cancer among patients with COPD. The five most common cancers after COPD diagnosis include lung cancer, liver cancer, colorectal cancer, prostate cancer and oesophageal cancer in male patients and lung cancer, breast cancer, colorectal cancer, liver cancer and stomach cancer in female patients. Patients with COPD had a higher risk of developing cancer and developed cancer within a shorter period of time compared with the patients without COPD. Patients with COPD had a high prevalence of comorbidities compared with the patients without COPD, including chronic kidney disease, liver disease, diabetes and dyslipidaemia. Patients with COPD had an elevated risk of developing cancer when they used more types of COPD medications compared with the patients without COPD. In patients with COPD, the risk of developing cancer was significant when they used more than two types of COPD medications compared with patients with COPD who only used one type of COPD medication.

Lung cancer and COPD {#s4b}
--------------------

Both COPD and lung cancer have high morbidity and mortality rates worldwide.[@R9] [@R10] Previous studies[@R11] [@R12] have shown that patients with COPD are at increased risk for the development of lung cancer, and lung cancer is an important cause of death in patients with COPD.[@R13] Patients with COPD are at increased risk for lung cancer because most of them have a history of smoking. Additionally, patients with COPD are of lower socioeconomic status compared with the general population, and socioeconomic status may affect quality of life, including environmental exposure to indoor and outdoor air pollution; these factors may influence the development of lung cancer.

Chronic inflammation after extracellular stimulation, such as tobacco smoking and occupational and environmental inhalants, play a key role in COPD and lung cancer. Thus, shared risk factors and inflammatory pathways lead to the similar pathological mechanisms of COPD and lung cancer.[@R14]

Liver cancer and COPD {#s4c}
---------------------

The α1-antitrypsin deficiency is one of the most common inherited disorders among white persons and predisposes individuals to COPD, cirrhosis and hepatomas.[@R15] [@R16] The α1-antitrypsin deficiency is not an important cause of childhood liver diseases in Southeast Asian populations[@R17] and is also rare in Taiwan. Liver cancer is one of the most common tumour types in Taiwan because Taiwan has a high prevalence of virus hepatitis, with ∼20% of the general population suffering from chronic hepatitis B virus infection and 4.4% of the population from chronic hepatitis C virus infection.[@R18]

Colorectal cancer and COPD {#s4d}
--------------------------

Colorectal cancer is one of the most common cancers in patients with COPD.[@R19] Patients with COPD experienced sensations of dyspnoea in their daily activities, and consequently tended to lead more sedentary lifestyles; sedentary behaviour may also increase the risk of colorectal cancer. A nationwide population-based observational study investigated the influence of COPD on intensive care unit admissions, medication treatments and mortality following colorectal cancer surgery.[@R20] The authors identified 7.9% of colorectal cancer surgery patients as having a COPD diagnosis, and in this population, more complications were noted after surgery, including higher ICU admission rates, more frequent need for mechanical ventilation, higher rates of requiring reoperation and more frequent inotropes/vasopressors. The 30-day mortality after surgery was 13.0% in patients with colorectal cancer and COPD and 5.3% in patients with colorectal cancer without COPD.

A study[@R21] demonstrated that COPD is one of the most common comorbid conditions in patients with colon cancer. The receipt of adjuvant therapy was related to COPD (55.2% vs 61.5% of patients with vs without COPD, respectively; OR 0.83; 95% CI 0.70 to 0.99), but patients with COPD and colon cancer had survival benefits after receipt of adjuvant therapy. Although COPD appeared to be a barrier to chemotherapy, chemotherapy can provide a survival benefit to patients who have colon cancer with COPD. Many colorectal cancers can be prevented through regular screening, and screening is also crucial in patients with COPD.

Prostate cancer and COPD {#s4e}
------------------------

Dysfunction in the hypothalamic--pituitary--gonadal axis, such as hypogonadotropic hypogonadism, has been noted in patients with COPD.[@R22] [@R23] The correlation between serum levels of testosterone and risk of prostate cancer is still controversial.[@R24] [@R25] One recent study found that patients with COPD had a significant reduction in total and free testosterone levels compared with controls.[@R26] The relationship between testosterone level and prostate cancer in patients with COPD needs further investigation. In our study, more than 80% of prostate cancers were diagnosed in men who were 60 years of age or older. A prostate-specific antigen-based screening test for prostate cancer may be warranted in the elderly male population with COPD.

Aerodigestive cancer and COPD {#s4f}
-----------------------------

It is widely accepted that smoking is a risk factor for oropharyngeal cancer, oesophageal cancer and COPD. In our study, development of cancers of the upper aerodigestive tract, including oropharyngeal and oesophageal cancers, were also common in patients with COPD. A cohort study among 17 774 men showed a positive association between smoking and subsequent cancers of the upper aerodigestive tract (relative risk, 2.02; 95% CI 1.01 to 4.06) with evidence of dose--response effects. Regular smoking will increase the risk of COPD and aerodigestive tract and lung cancers.[@R27] In addition to the same risk factor of smoking, the higher risk of aerodigestive cancers in patients with COPD can be partially explained by socioeconomic status. A previous study showed that the risk of aerodigestive cancers cannot be entirely explained by smoking, alcohol consumption and diet. Socioeconomic status was also a risk factor for upper aerodigestive tract cancers.[@R28] There is growing recognition of the importance of systematic examination of the oral cavity, oropharynx and neck, which can detect precancers and cancers at an early and curable stage in patients with COPD with a history of smoking.

Cancer types in patients with COPD {#s4g}
----------------------------------

Our study showed a positive association between COPD and the subsequent development of cancer. The AHR of developing cancer in patients with COPD was 2.8 (95% CI 2.6 to 3.1) compared with patients without COPD after adjusting for age, sex and comorbidities. In a previous study of the incidence of cancer, smoking increased the risk of cancer of the oropharynx, upper aerodigestive tract and lung.[@R27] From our analysis, in addition to the cancers aforementioned, common cancer types diagnosed with high frequency in patients with COPD included liver, colon and breast cancers.

A population-based study[@R29] revealed that 12% of all patients with cancer had COPD at the time of cancer diagnosis, with ∼15% of those patients over the age of 65. In addition to lung cancer, there was no difference in the stage at diagnosis between patients with cancer with or without COPD. After using a multivariate Cox regression model, the survival rate was poor in patients with COPD, especially for elderly patients with colon, rectum, larynx, prostate or urinary bladder cancer.

Another study conducted in Taiwan also used the NHIRD, but the researchers presented the risk of cancer in COPD using a standardised incidence ratio. From 1995 to 2008, they enrolled 50 875 patients with COPD over 20 years of age and found that head and neck, oesophageal, lung and mediastinal, breast, and prostate cancer were higher in patients with COPD compared with the general population. In our study, we further analysed the prescription pattern, including bronchodilators and steroid, in all patients with COPD from 1 January 2000 to 31 December 2011 with stricter inclusion criteria which aged more than 40 years and visit at least three ambulatory visits for COPD. In our study, we analysed the comorbidities in patients with and without COPD and HR of developing cancer in relation to baseline characteristics which was not performed in Chiang and colleagues' study. We also found that the more bronchodilators patients with COPD used, the more risk of developing cancer. If patients with COPD used more than two bronchodilators representing COPD severity, the disease severity of COPD may be associated with increasing cancer risk.

In summary, in Chiang\'s study, they included patients aged more than 20 years. We enrolled patients aged more than 40 years. Patients with COPD in our study were treated with COPD medications and non-COPD groups did not get treated with any COPD medications. In Chiang\'s study, they did not survey the COPD medications. Our study exactly matches by age and gender with the Cox model and analysed the comorbidities. In Chiang\'s study, they used SIR to analyse the risk of cancer. SIR cannot adjust comorbidity and medications.

In figure [2](#BMJOPEN2016013195F2){ref-type="fig"}, consistent with the results of Chiang\'s studies, patients with COPD had a higher risk of lung, aerodigestive and prostate cancer. There was difference in association between COPD and cancers in our study compared with Chiang\'s study after adjusting for age and gender. In our study, patients with COPD had a higher risk of liver and colorectal cancer compared with patients without COPD. Although the risk of head and neck cancer was higher in patients with COPD compared with general population in Chiang\'s study, there was no significant difference in risk in our study after adjusting for age and gender. In addition to lung and aerodigestive cancer, we suggest that patients with COPD follow-up cancer screening may include liver and colorectal cancer.

Kornum *et al*[@R30] used the Danish National Registry of Patients and their nationwide cancer registry databases to show the incidence of various cancers in 236 494 patients with COPD from 1980 to 2008. They included patients aged 40 years or older with COPD. Patients were enrolled after a first-time hospitalisation, outpatient clinic visit or a visit to an emergency department with a diagnosis of COPD from ICD-8 or ICD-10 codes. The researchers focused on tobacco-related and alcohol-related cancers, but they did not evaluate comorbidities and medications in patients with COPD. They found that lung, aerodigestive and liver cancers were increased in patients with COPD.

Limitations {#s4h}
-----------

One major limitation was that some of the data, including histories of cigarette smoking, pulmonary function, degree of dyspnoea, COPD severity and cancer staging, were not available from the claims database. We used the database to demonstrate that COPD was significantly associated with a high risk of cancer, regardless of COPD severity. As a representation of COPD severity, we also divided the COPD population into three groups according to the number of medications they used to treat COPD. After the stratification, we found that patients who used more COPD medications were at a higher risk of developing cancer. Other limitations should be acknowledged, including that the data were based on insurance records that lacked consideration of other factors associated with COPD and cancer, such as lifestyle choices, physical activity and socioeconomic status, which may have led to possible errors. The limitations of the analysis based on the database include an inability to truly characterise the patients and controls.

The study was a nationwide cohort study; we believe that the large number of participants, the comprehensive enrolment of patients with COPD and the long-term follow-up ensured that the data are normally distributed and that the results are significant.

Conclusion {#s5}
==========

In addition to lung cancer, patients with COPD have a higher risk of developing other types of cancer, and physicians should closely monitor and follow-up with these patients.
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